Details
Stereochemistry | ACHIRAL |
Molecular Formula | Ca |
Molecular Weight | 40.078 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 2 |
SHOW SMILES / InChI
SMILES
[Ca++]
InChI
InChIKey=BHPQYMZQTOCNFJ-UHFFFAOYSA-N
InChI=1S/Ca/q+2
Molecular Formula | Ca |
Molecular Weight | 40.078 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Sources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479
Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
Title | Date | PubMed |
---|---|---|
Studies on the calcemic effect of intravenous secretin in humans. | 1975 Jun |
|
Ni2+ transport by the human Na+/Ca2+ exchanger expressed in Sf9 cells. | 1999 May |
|
Aluminum is a weak agonist for the calcium-sensing receptor. | 1999 May |
|
Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. | 1999 Nov |
|
Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity. | 1999 Sep 20 |
|
Cytosolic [Ca(2+)] modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells. | 2000 Aug |
|
Oim mice exhibit altered femur and incisor mineral composition and decreased bone mineral density. | 2000 Aug |
|
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. | 2000 Dec |
|
Vanadate induces calcium signaling, Ca2+ release-activated Ca2+ channel activation, and gene expression in T lymphocytes and RBL-2H3 mast cells via thiol oxidation. | 2000 Jan 15 |
|
NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways. | 2000 Jul 17 |
|
Hepatocyte growth factor disrupts cell contact and stimulates an increase in type 3 inositol triphosphate receptor expression, intracellular calcium levels, and apoptosis of rat ovarian surface epithelial cells. | 2000 Jun |
|
Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors. | 2000 Nov |
|
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. | 2000 Nov |
|
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats. | 2000 Nov 10 |
|
Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity. | 2001 Aug 28 |
|
Complement activation in factor D-deficient mice. | 2001 Dec 4 |
|
Molecular and functional characterization of a family of rat brain T-type calcium channels. | 2001 Feb 9 |
|
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow. | 2001 Feb 9 |
|
Endothelin- and sarafotoxin-induced receptor-mediated calcium mobilization in a clonal murine osteoblast-like cell line, MC3T3-E1/B. | 2001 Jun |
|
Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. | 2001 Jun |
|
Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. | 2001 Mar 15 |
|
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. | 2001 Nov |
|
Regression of ventral striatum hypometabolism after calcium/calcitriol therapy in paroxysmal kinesigenic choreoathetosis due to idiopathic primary hypoparathyroidism. | 2001 Nov |
|
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors. | 2001 Nov 1 |
|
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. | 2001 Oct 26 |
|
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. | 2001 Sep |
|
Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism. | 2001 Sep |
|
CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells. | 2002 Feb |
|
Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit. | 2002 Sep |
|
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. | 2002 Sep 6 |
|
A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs. | 2002 Sep 6 |
|
Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial. | 2015 Aug 12 |
|
Dietary interventions for mineral and bone disorder in people with chronic kidney disease. | 2015 Sep 16 |
|
Lactose behaviour in the presence of lactic acid and calcium. | 2016 Aug |
Sample Use Guides
Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:07:09 GMT 2025
by
admin
on
Mon Mar 31 18:07:09 GMT 2025
|
Record UNII |
2M83C4R6ZB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
13959-2
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
53087-3
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
83064-6
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
WHO-ATC |
A12AA07
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
NCI_THESAURUS |
C68241
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
49936-8
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
53139-2
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
50837-4
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
59472-1
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
17863-2
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
12180-6
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
NDF-RT |
N0000184168
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
14415-4
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
WHO-ATC |
A12AA20
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
NCI_THESAURUS |
C597
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
41645-3
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
57333-7
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
17864-0
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
38230-9
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
34581-9
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
46093-1
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
41644-6
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
47596-2
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
49935-0
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
54367-8
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
53138-4
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
53140-0
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
59470-5
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
42567-8
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
54366-0
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
59471-3
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
53088-1
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
1994-3
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
47598-8
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
1995-0
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
59473-9
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
50838-2
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
41646-1
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
||
|
LOINC |
19072-8
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
39123
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | |||
|
N0000009252
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | Increased Coagulation Factor Activity [PE] | ||
|
2M83C4R6ZB
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | |||
|
2M83C4R6ZB
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | |||
|
39099
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | |||
|
DTXSID7037638
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | |||
|
SUB121174
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | |||
|
29108
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | |||
|
DB14577
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | |||
|
100000144534
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | |||
|
N0000166192
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | Cations, Divalent [Chemical/Ingredient] | ||
|
39124
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | |||
|
C61660
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | |||
|
1316581
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | RxNorm | ||
|
14127-61-8
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY | |||
|
271
Created by
admin on Mon Mar 31 18:07:09 GMT 2025 , Edited by admin on Mon Mar 31 18:07:09 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |